Atara Biotherapeutics Announces Board Transition, Welcomes Veteran Investor Brian Cherry as Director
Atara Biotherapeutics, Inc., a clinical-stage biotechnology company focused on advancing T-cell immunotherapies for cancer and autoimmune diseases, has announced a significant change to its Board of Directors. The company revealed that longtime board member Carol Gallagher, Pharm.D., will be departing from the board after more than a decade of service, while experienced investor and business leader Brian Cherry has been appointed as a new director.
The leadership transition comes as Atara continues to advance its pipeline of allogeneic T-cell therapies based on its proprietary Epstein-Barr virus (EBV) T-cell platform. The company believes the addition of Cherry’s financial and strategic expertise will complement its existing leadership team and support long-term growth initiatives, while also marking the conclusion of an important chapter in the company’s governance history with Gallagher’s departure.
Recognizing More Than a Decade of Service
Carol Gallagher’s departure closes a significant period of involvement with Atara Biotherapeutics. Having served on the company’s Board of Directors for approximately thirteen years, Gallagher played a key role during a transformative era for the biotechnology company as it evolved from an emerging enterprise into a recognized innovator in the field of cell therapy and immunotherapy.
Throughout her tenure, Gallagher contributed to numerous strategic decisions, governance initiatives, and corporate milestones that helped shape the company’s direction. Her experience in the pharmaceutical and biotechnology sectors provided valuable insight as Atara expanded its research and development programs, pursued clinical advancement opportunities, and navigated the complexities of the rapidly evolving biotechnology landscape.
According to Atara President and Chief Executive Officer Cokey Nguyen, Gallagher’s contributions extended well beyond traditional board responsibilities.
Nguyen expressed appreciation on behalf of the company and its shareholders, noting that Gallagher had been a cornerstone of the board for many years. He highlighted her willingness to serve in multiple leadership capacities throughout her tenure and acknowledged the dedication she consistently demonstrated toward supporting the company’s mission and strategic objectives.
The company also extended its best wishes to Gallagher as she moves forward into the next phase of her professional career.
A Period of Transformation for Atara
Gallagher’s time on the board coincided with a period of significant development for Atara Biotherapeutics.
During these years, the company strengthened its position within the immunotherapy field, focusing on the development of allogeneic T-cell therapies designed to address serious diseases with significant unmet medical needs.
Atara’s scientific approach centers on harnessing the power of T cells, a critical component of the immune system, to target and combat cancer and autoimmune conditions. Unlike traditional therapies, the company’s platform seeks to utilize off-the-shelf allogeneic T-cell therapies derived from healthy donors, potentially offering scalable and accessible treatment options for patients.
The company’s work with Epstein-Barr virus-specific T-cell therapies has generated considerable interest within the biotechnology industry as researchers continue to explore novel immunotherapy approaches capable of delivering durable clinical benefits.
Throughout this evolution, board leadership played an important role in guiding corporate strategy, supporting clinical development efforts, and ensuring effective governance.
Welcoming Brian Cherry to the Board
As Gallagher departs, Atara is bringing in a new director whose background reflects extensive experience in finance, investment management, and corporate growth.
Brian Cherry joins the Board of Directors with more than 25 years of experience investing in and helping build businesses across multiple industries. His career spans a broad range of sectors, including healthcare, industrial operations, business services, financial services, and consumer products.
Over the course of his professional career, Cherry has participated in transactions and investments involving companies with a combined enterprise value exceeding $25 billion. This experience has provided him with substantial expertise in evaluating growth opportunities, capital deployment strategies, acquisitions, and long-term value creation.
Atara believes these skills will provide an important complement to the board’s existing capabilities as the company continues to navigate the evolving biotechnology marketplace.
Extensive Private Equity Leadership Experience
A significant portion of Cherry’s career was spent at Oak Hill Capital, a prominent private equity investment firm known for partnering with businesses across diverse industries.
As a Managing Partner at Oak Hill Capital, Cherry was responsible for identifying investment opportunities, overseeing portfolio companies, and helping management teams execute strategic growth plans.
Private equity leadership often requires balancing operational priorities with long-term financial performance, a perspective that can be particularly valuable for growth-oriented biotechnology companies seeking to maximize shareholder value while investing in innovation.
His experience evaluating mergers, acquisitions, strategic partnerships, and financing opportunities may prove beneficial as Atara continues to assess pathways for advancing its business objectives and clinical programs.
Broad Governance and Board Experience
Beyond his investment background, Cherry brings substantial governance experience through service on numerous corporate and nonprofit boards.
Over the years, he has served on the boards of more than a dozen private and public companies, providing oversight and strategic guidance across a variety of industries.
This broad governance experience has given him exposure to complex business challenges, risk management considerations, operational transformation initiatives, and long-term strategic planning efforts.
In addition to his corporate board responsibilities, Cherry has been involved with several respected educational and philanthropic organizations.
His service includes participation on the board of the U.S. Air Force Academy Foundation as well as involvement with the Undergraduate Financial Aid Leadership Council at the University of Pennsylvania.
These roles reflect a commitment not only to business leadership but also to education and community engagement.
Strong Academic Foundation
Cherry’s educational background includes degrees from two highly regarded institutions.
He earned his undergraduate degree from Princeton University before pursuing graduate studies at The Wharton School, where he received his Master of Business Administration.
His academic training, combined with decades of investment and boardroom experience, has contributed to a reputation as a strategic leader with expertise in corporate growth and value creation.
Supporting Long-Term Shareholder Value
Commenting on the appointment, Nguyen emphasized that Cherry’s skills align closely with the company’s strategic priorities.
He noted that Cherry’s experience in capital allocation and strategic acquisitions will support Atara’s efforts to build sustainable long-term value for shareholders.
Biotechnology companies often face complex decisions regarding research investments, partnership opportunities, financing strategies, and business development initiatives. Leadership teams frequently rely on directors with diverse professional backgrounds to help navigate these challenges and identify opportunities that strengthen both scientific and financial performance.
Nguyen expressed confidence that Cherry’s perspective would contribute meaningfully to future discussions involving corporate strategy and growth.
He also indicated that the management team looks forward to working closely with Cherry as the company advances its mission and evaluates future opportunities.
Positioning Atara for the Future
The board transition comes at an important time for Atara Biotherapeutics as the company continues to focus on advancing innovative immunotherapy approaches designed to address serious diseases.
The biotechnology sector remains highly competitive and rapidly evolving, with companies increasingly seeking experienced leaders capable of guiding organizations through scientific, operational, and financial complexities.
By adding a director with extensive investment and strategic experience, Atara aims to strengthen its governance structure while positioning itself to capitalize on future opportunities.
At the same time, the company’s acknowledgment of Gallagher’s long service underscores the importance of continuity and institutional knowledge in supporting long-term success.
As Atara Biotherapeutics enters its next phase of growth, the company’s leadership transition reflects both appreciation for past contributions and a focus on future opportunities.
Carol Gallagher leaves behind a legacy of more than a decade of dedicated service during a period of significant advancement for the organization. Her guidance helped support Atara’s development as a leader in T-cell immunotherapy and contributed to the company’s ongoing efforts to improve outcomes for patients with cancer and autoimmune diseases.
Meanwhile, Brian Cherry joins the board with a wealth of experience in investment management, corporate governance, and strategic growth. His appointment brings additional expertise that Atara believes will support its mission of delivering innovative therapies while creating long-term value for shareholders.
Together, these changes represent an important milestone in the company’s evolution as it continues pursuing transformative therapies through its pioneering allogeneic EBV T-cell platform and broader immunotherapy pipeline.
About Atara Biotherapeutics, Inc.
Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. With cutting-edge science and differentiated approach, Atara is the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Our advanced and versatile T-cell platform does not require T-cell receptor or HLA gene editing and forms the basis of a diverse portfolio of investigational therapies that target EBV, the root cause of certain diseases. Atara is headquartered in Southern California.
